Odonate Therapeutics
 
 

OUR COMPANY

We are a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several properties that make it unique among taxanes, including:

  • Oral administration with a low pill burden;

  • A long (~8-day) terminal plasma half-life (t1/2) in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing;

  • No history of hypersensitivity (allergic) reactions; and

  • Significant activity against chemotherapy-resistant tumors.

In patients with metastatic breast cancer (MBC), tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies. Tesetaxel currently is the subject of three studies in breast cancer, including a multinational, multicenter, randomized, Phase 3 study in patients with MBC, known as CONTESSA (clinicaltrials.gov). Positive results of CONTESSA were recently presented at the 2020 San Antonio Breast Cancer Symposium (SABCS). We plan to submit a New Drug Application for tesetaxel to the U.S. Food and Drug Administration in mid-2021. Our goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.

OUR NAME

odo·nate
\ˈō-də-ˌnāt, ō-ˈdä-(ˌ)nāt\

n. (Zoology) an insect, such as a dragonfly, that belongs to the zoological group Odonata

Dragonfly Symbolism
“The dragonfly’s agile flight and its ability to move in all six directions exude a sense of power and poise - something that comes only with age and maturity...The awe inspiring aspect is how the dragonfly accomplishes its objectives with utmost simplicity, effectiveness and well, if you look at proportions, with 20 times as much power in each of its wing strokes when compared to the other insects. The best part is that the dragonfly does it with elegance and grace that can be compared to a veteran ballet dancer.” 
 
 

OUR VALUES

Focus on the Patient
We are dedicated to improving the lives of patients in need
Operate with Integrity
Our word is our most valuable asset
Bring Passion
We take pride in our work and strive for excellence in all that we do
Be Creative
The best way is often yet to be discovered
Foster Unity
We are one community
Be Kind
We believe in the inherent goodness of people and strive to treat everyone with kindness
Promote Equal Opportunity
Every person should be offered an opportunity to achieve success in all aspects of life
Give Forward
We receive happiness from helping those in need within our local and global community
Find Joy
We support personal goals for physical, mental and spiritual well-being
 

BOARD OF DIRECTORS

Kevin Tang
Chairman and Chief Executive Officer
Aaron Davis
Director
Craig Johnson
Director
Laura Johnson
Director
Robert Rosen
Director
 

Kevin Tang

Chairman and Chief Executive Officer

 

Mr. Tang has served as our Chairman and Chief Executive Officer since the Company’s inception in 2013. He also serves as President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. Since 2014, Mr. Tang has served as a director and Chairman of La Jolla Pharmaceutical Company. From 2009 to 2020, he served as a director of Heron Therapeutics, Inc. and, from 2012 to 2020, served as Chairman. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, Mr. Tang served as a director of Penwest Pharmaceuticals Co. In 2006, he co-founded Ardea Biosciences, Inc. and served as a director from inception through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, Mr. Tang served as a director of Trimeris, Inc. From 1993 to 2001, he held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.

 

 

Aaron Davis

Director

 

Mr. Davis has served as a director since 2016. Since 2012, he has served as Chief Executive Officer of Boxer Capital, the healthcare arm of Tavistock Group. Mr. Davis co-founded Boxer Capital in 2005 and, prior to being appointed Chief Executive Officer, served as Portfolio Manager. He also serves as Chairman of CiVi Biopharma, Inc., a director of Sojournix, Inc. and a director of Mirati Therapeutics, Inc. From 2006 to 2008, Mr. Davis served as a director of Kalypsys, Inc. From 2000 to 2004, he worked in the Global Healthcare Investment Banking and Private Equity Group at UBS Warburg, LLC. Mr. Davis received an M.A. degree in biotechnology from Columbia University and a B.B.A. degree in finance from Emory University.

 

 

Craig Johnson

Director

 

Mr. Johnson has served as a director since 2017. He also serves as a director of Heron Therapeutics, Inc., a director of La Jolla Pharmaceutical Company and a director of Mirati Therapeutics, Inc. From 2015 to 2018, Mr. Johnson served as a director of GenomeDx Biosciences, Inc. From 2008 until its acquisition by AstraZeneca PLC in 2012, he served as a director of Ardea Biosciences, Inc., and, from 2011 to 2014, Mr. Johnson served as a director of Adamis Pharmaceuticals Corporation. From 2011 to 2012, he served as Chief Financial Officer of PURE Bioscience, Inc., and, from 2010 to 2011, Mr. Johnson served as Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. From 2004 through its acquisition by Raptor Pharmaceuticals Corp. in 2009, he served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. and, from 2009 to 2010, Mr. Johnson served as Vice President of a wholly-owned subsidiary of Raptor Pharmaceuticals Corp. From 1994 to 2004, he held various positions at MitoKor, Inc., most recently serving as Chief Financial Officer and Senior Vice President of Operations. Mr. Johnson received a B.B.A. degree in accounting from the University of Michigan-Dearborn.

 

 

Laura Johnson

Director

 

Ms. Johnson has served as a director since 2018. She serves as President and Chief Executive Officer of Next Generation Clinical Research Consulting, Inc., a contract research organization servicing the pharmaceutical industry that she founded in 1999. Additionally, Ms. Johnson serves as the President and Chief Executive Officer for Eufaeria Biosciences, Inc., a biotechnology company that she founded in 2016. She serves as a director of La Jolla Pharmaceutical Company. Ms. Johnson is also a founder and serves as a director of Sb Bancorp, Inc. and Settlers Bank, Inc. Ms. Johnson received a nursing degree from The University of the State of New York-Albany.

 

 

Robert Rosen

Director

 

Mr. Rosen has served as a director since 2017. Since 2014, he has served as a director of La Jolla Pharmaceutical Company. From 2013 to 2019, Mr. Rosen served as President and as a director of Heron Therapeutics, Inc., and, from 2012 to 2013, served as Senior Vice President and Chief Commercial Officer of Heron Therapeutics, Inc. From 2014 to 2015, he served as a director of Conkwest, Inc. (now NantKwest, Inc.). In 2012, Mr. Rosen served as Managing Partner of Scotia Nordic LLC, a life sciences advisory firm. From 2011 to 2012, he served as Senior Vice President of Global Commercial Operations at Dendreon Corporation. From 2005 to 2011, Mr. Rosen served as Global Head of Oncology at Bayer HealthCare Pharmaceuticals. From 2002 to 2005, he served as Vice President of the Oncology Business Unit at Sanofi-Synthèlabo Inc. Mr. Rosen received a B.S. degree in pharmacy from Northeastern University.

 
 
 
 
 

MANAGEMENT

Kevin Tang
Chairman and Chief Executive Officer
 
Michael Hearne
Chief Financial Officer
Stew Kroll
Chief Development Officer
 
Joseph O’Connell, M.D.

Chief Medical Officer

 
Thomas Wei
Chief Scientific Officer
 
Ryan Cole
Senior Vice President of Operations
Kim Ma
Senior Vice President of Clinical Operations
Tracey McKennon
Senior Vice President of Quality Assurance
 
Steven Pfeiffer, Ph.D.
Senior Vice President of Technical Operations
 
Jennifer Schroeder
Senior Vice President of Program Management and Technology
Christian Gagel
Vice President of Finance and Accounting
Jill Krause
Vice President of Clinical Quality and Training
 
 
Kevin Tang

Chairman and Chief Executive Officer

 

Mr. Tang has served as our Chairman and Chief Executive Officer since the Company’s inception in 2013. He also serves as President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. Since 2014, Mr. Tang has served as a director and Chairman of La Jolla Pharmaceutical Company. From 2009 to 2020, he served as a director of Heron Therapeutics, Inc. and, from 2012 to 2020, served as Chairman. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, Mr. Tang served as a director of Penwest Pharmaceuticals Co. In 2006, he co-founded Ardea Biosciences, Inc. and served as a director from inception through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, Mr. Tang served as a director of Trimeris, Inc. From 1993 to 2001, he held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.

 

Michael Hearne

Chief Financial Officer

 

Mr. Hearne has served as our Chief Financial Officer since 2018 and previously as Vice President of Finance and Accounting from 2015 to 2018. Since 2015, he has served as Chief Financial Officer of Tang Capital Management, LLC, a life sciences-focused investment company. Since 2020, Mr. Hearne has also served as Chief Financial Officer of La Jolla Pharmaceutical Company. From 2014 to 2015, he served as a partner at Weaver & Tidwell, LLP. Mr. Hearne started his career in public accounting at Coopers & Lybrand. Mr. Hearne received a B.S. degree in accounting and a masters of accountancy, taxation from Brigham Young University and is a Certified Public Accountant (inactive) in the state of California.

 

Stew Kroll

Chief Development Officer

 

Mr. Kroll has served as our Chief Development Officer since 2018 and previously held various positions, most recently serving as Senior Vice President of Biometrics and Regulatory Strategy, from 2017 to 2018. Since 2017, he has also held various positions at La Jolla Pharmaceutical Company, most recently serving as Chief Development Officer since 2020. From 2005 to 2016, Mr. Kroll held various positions at Threshold Pharmaceuticals, Inc., most recently serving as Chief Operating Officer. From 2000 to 2005, he served as Senior Director of Biostatistics at Corixa Corporation. From 1997 to 2000, Mr. Kroll held various positions at Coulter Pharmaceutical, Inc., most recently serving as Director of Biostatistics. Mr. Kroll received a B.A. degree and an M.A. degree in statistics from the University of California, Berkeley.

Joseph O'Connell, M.D.

Chief Medical Officer

 

Dr. O’Connell has served as our Chief Medical Officer since 2017. From 2015 to 2017, he served as Vice President, Medical and Scientific Affairs, Hematology and Oncology at inVentiv Health Clinical, LLC. From 2007 to 2015, Dr. O’Connell held various positions at Pfizer Inc., most recently serving as Senior Director and Asset Global Clinical Lead for Oncology. Prior to 2007, he practiced adult medical oncology for more than 15 years, including at the Yale Cancer Center. Dr. O’Connell received a B.S. degree in biology from Fordham University and an M.D. degree from the State University of New York, and completed his Oncology Fellowship at Memorial Sloan Kettering Cancer Center.

 

Thomas Wei

Chief Scientific Officer

 

Mr. Wei has served as our Chief Scientific Officer since 2018 and previously as our Senior Vice President of Research and Development from 2015 to 2018. Since 2015, he has served as Managing Director at Tang Capital Management, LLC, a life sciences-focused investment company. From 2009 to 2015, Mr. Wei served as a managing director and biotechnology equity research analyst at Jefferies LLC. From 2003 to 2009, he served as a biotechnology equity research analyst at Piper Jaffray, most recently serving as a managing director. From 1998 to 2003, Mr. Wei served as a biotechnology equity research analyst at Deutsche Bank AG and Adams, Harkness & Hill Inc. Mr. Wei received an A.B. degree in biochemical sciences from Harvard University and an M.B.A. degree from Oxford University.

 

 

 

Ryan Cole

Senior Vice President of Operations

 

Mr. Cole has served as our Senior Vice President of Operations since January 2021 and previously held various positions, most recently serving as Vice President of Operations, from 2014 to 2020. From 2012 to 2014, he served as a senior financial analyst in mergers and acquisitions at Thermo Fisher Scientific Inc. From 2009 to 2012, Mr. Cole held various positions at Ernst & Young LLP, most recently serving as an assurance senior. Mr. Cole received a B.S. degree in accounting from Santa Clara University and is a Certified Public Accountant (inactive) in the state of California. 

Kim Ma

Senior Vice President of Clinical Operations

Ms. Ma has served as our Senior Vice President of Clinical Operations since January 2021 and previously held various positions, most recently serving as Vice President of Clinical Operations, from 2017 to 2020. From 2014 to 2017, she held various positions at Pfizer Inc., most recently serving as a director in clinical project management. From 2011 to 2014, Ms. Ma served as a senior project manager for the Pfizer Strategic Business Unit at ICON PLC. From 2008 to 2011, she served as a clinical project manager at Medtronic Diabetes. Ms. Ma received a B.S. degree in biomedical engineering from the University of Southern California and a M.S. degree in regulatory science from the University of Southern California School of Pharmacy.

Tracey McKennon

Senior Vice President of Quality Assurance

 

Ms. McKennon has served as our Senior Vice President of Quality Assurance since January 2021 and previously as our Vice President of Quality Assurance from 2018 to 2020. From 2004 to 2018, she held various positions at Seattle Genetics, Inc., most recently serving as Executive Director, Quality Assurance. From 1998 to 2004, Ms. McKennon held various positions at Chiron Corporation, most recently serving as a contract manufacturing manager. From 1996 to 1998, she served as a research associate at Eli Lilly and Company. Ms. McKennon received a B.S. degree in forensic and analytical chemistry from the University of Strathclyde and a M.S. degree in organic chemistry from Colorado State University.

 

 

Steven Pfeiffer, Ph.D.

Senior Vice President of Technical Operations

 

Dr. Pfeiffer has served as our Senior Vice President of Technical Operations since January 2021 and previously as our Vice President of Technical Operations from 2016 to 2020. From 2015 to 2016, he held various positions at Horizon Pharma PLC, most recently serving as Senior Director of Manufacturing and Development. From 2011 to 2015, Dr. Pfeiffer held various positions at Kythera Biopharmaceuticals, Inc., most recently serving as Associate Director of Product Research, Development and Manufacturing. From 2009 to 2010, he served as Associate Director at Sai Advantium Pharma Limited. From 2005 to 2009, Dr. Pfeiffer held various positions at Gilead Sciences, Inc., most recently serving as a research scientist. Dr. Pfeiffer received a Ph.D. degree in chemistry from the University of California, Santa Barbara, an M.B.A. degree from California State University, East Bay, and a B.S. degree in chemistry from the University of Arizona.

Jennifer Schroeder

Senior Vice President of Program Management and Technology

 

Ms. Schroeder has served as our Senior Vice President of Program Management and Technology since January 2021 and previously held various positions, most recently serving as Vice President of Program Management and Technology, from 2018 to 2020. From 1998 to 2018, she held various positions at Pfizer Inc., most recently serving as Senior Director, Head of Strategic Initiatives in Global Product Development. Ms. Schroeder received a B.S. degree in English from Eastern Michigan University and an M.A. degree in English from the University of Toledo.

Christian Gagel

Vice President of Finance and Accounting

 

Mr. Gagel has served as our Vice President of Finance and Accounting since January 2021 and previously held various positions, most recently serving as Executive Director of Finance and Accounting, from 2016 to 2020. From 2008 to 2016, he held various positions at Ernst & Young LLP, most recently serving as an assurance senior manager. Mr. Gagel received a B.S. degree in accounting from Santa Clara University and is a Certified Public Accountant in the state of California.

Jill Krause

Vice President of Clinical Quality and Training

 

Ms. Krause has served as our Vice President of Clinical Quality and Training since 2020 and previously held various positions, most recently serving as Vice President of Clinical Training, from 2017 to 2019. From 1999 to 2017, she held various positions at Pfizer Inc., most recently serving as Director and Clinical Operations Program Lead. Ms. Krause received a B.S. degree in business administration and an M.B.A. degree from Eastern Michigan University.

 
 
 
 
 
 
 
 
 
 
 
 

Contact Us          Careers          Privacy Notice          Terms of Use

© 2020 Odonate Therapeutics, Inc.